Eli Lilly Gives 340B Hospitals Five-Day Ultimatum on Claims Data

Daily Biopharma Digest — June 2, 2026

• Eli Lilly issued a five-day ultimatum to 340B hospitals — submit claims data or lose discounts — escalating tensions over duplicate discount allegations.
• At ASCO 2026, early data from Lilly’s newly acquired Kelonia asset KLN-1010 showed promising tolerability in multiple myeloma.
• Pfizer’s Talzenna/Xtandi combo demonstrated first-line potential in HRR-altered metastatic prostate cancer.
• Abivax plunged 43% as cancer cases in its inflammatory bowel disease trial clouded promising data and imperiled takeover prospects.

What to Watch

• 340B Enforcement Precedent — Whether HRSA intervenes in Lilly’s data-sharing ultimatum could set precedent for how manufacturers balance duplicate discount prevention with program access obligations, potentially triggering copycat actions industry-wide.
• Abivax Safety Investigation — Causality assessment of cancer cases in Abivax’s IBD trial will determine whether this represents a mechanism-based class concern or idiosyncratic toxicity, with implications for competitive programs targeting similar pathways.
• In Vivo Cell Therapy Race — ASCO 2026 data suggest the in vivo CAR-T field is maturing rapidly; watch for head-to-head and durability data to clarify whether these platforms can challenge established ex vivo approaches in hematologic malignancies.
• PARP Inhibitor Label Expansion — Pfizer’s TALAPRO-3 success in first-line prostate cancer could trigger label expansion battles as PARP inhibitor manufacturers compete to establish their agents as preferred partners with androgen receptor inhibitors across disease states.